Loading clinical trials...
Loading clinical trials...
This study will investigate the effect of renal impairment on the pharmacokinetics/pharmacodynamics of GK Activator (2) in patients with type 2 diabetes, and will evaluate the effect of renal function...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Hoffmann-La Roche
NCT06525259 · Diabetes Mellitus Type 2, Childhood-Onset
NCT05934409 · Diabetes Mellitus Type 2
NCT07011147 · Type 1 Diabetes (T1D), Type 2 Diabetes, and more
NCT03821636 · Diabetes Mellitus Type 2 in Obese
NCT06957093 · Diabetes Mellitus Type 2 (T2DM), Artificial Intelligence (AI)
Cypress, California
Austin, Texas
Dallas, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions